NCT06966141
A Real World Study of Sacituzumab Govitecan
At risk: Primary completion moved 4 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Start date: Aug 12, 2024 to Feb 5, 2025
- Eligibility criteria expanded, about 14 words
- Primary completion pushed from Aug 1, 2026 to Dec 1, 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
PFS
Timeframe: Six months after the last patient was enrolled
ORR
Timeframe: Up to approximately 12 weeks
Arms and interventions
Patients received SG
HER2-negative breast cancer patients who received SG in the advanced stage
Sites
1 site in 1 country
- Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality, China